Inactivation of Factor XII Active Fragment in Normal Plasma. Predominant Role of C-1-inhibitor
Overview
Affiliations
To define the factors responsible for the inactivation of the active fragment derived from Factor XII (Factor XIIf ) in plasma, we studied the inactivation kinetics of Factor XIIf in various purified and plasma mixtures. We also analyzed the formation of 125I-Factor XIIf -inhibitor complexes by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). In purified systems, the bimolecular rate constants for the reactions of Factor XIIf with C-1-inhibitor, alpha 2-antiplasmin, and antithrombin III were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively. Furthermore, SDS-PAGE analysis revealed that 1:1 stoichiometric complexes were formed between 125I-Factor XIIf and each of these three inhibitors. In contrast, kinetic and SDS-PAGE studies indicated that Factor XIIf did not react with alpha 1-antitrypsin or alpha 2-macroglobulin. The inactivation rate constant of Factor XIIf by prekallikrein-deficient plasma was 14.4 X 10(-2) min-1, a value that was essentially identical to the value predicted from the studies in purified systems (15.5 X 10(-2) min-1). This constant was reduced to 1.8 X 10(-2) min-1 when Factor XIIf was inactivated by prekallikrein-deficient plasma that had been immunodepleted (less than 5%) of C-1-inhibitor. In addition, after inactivation in normal plasma, 74% of the active 125I-Factor XIIf was found to form a complex with C-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III. Furthermore, 42% of the labeled enzyme was still complexed with C-1-inhibitor when 125I-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional C-1-inhibitor. This study quantitatively demonstrates the dominant role of C-1-inhibitor in the inactivation of Factor XIIf in the plasma milieu.
Rezvani-Sharif A, Lioe H, Dower S, Pelzing M, Panousis C, Harvie D PLoS Comput Biol. 2024; 20(11):e1012552.
PMID: 39495806 PMC: 11563367. DOI: 10.1371/journal.pcbi.1012552.
Increased thromboinflammatory load in hereditary angioedema.
Gramstad O, Schjalm C, Mollnes T, Nielsen E Clin Exp Immunol. 2023; 214(2):170-181.
PMID: 37561062 PMC: 10714191. DOI: 10.1093/cei/uxad091.
High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism.
Grover S, Snir O, Hindberg K, Englebert T, Braekkan S, Morelli V J Thromb Haemost. 2023; 21(7):1849-1860.
PMID: 37003465 PMC: 11112258. DOI: 10.1016/j.jtha.2023.03.024.
Ferrara A, Bova M, Petraroli A, Marasco D, Payre C, Fortuna S Immunol Res. 2022; 71(1):70-82.
PMID: 36385678 PMC: 9845149. DOI: 10.1007/s12026-022-09331-7.
Urwyler P, Moser S, Trendelenburg M, Sendi P, Osthoff M Mol Immunol. 2022; 150:99-113.
PMID: 36030710 PMC: 9393183. DOI: 10.1016/j.molimm.2022.08.008.